Onco Wiki / Bandera roja

Esófago de Barrett (metaplasia intestinal del esófago distal con células de cás...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDRF-BARRETTS-ESOPHAGUS-PREVENTION
TipoSeñal de alerta
Situaciónreviewed 2026-05-18 | pending_clinical_signoff
EnfermedadesDIS-ESOPHAGEAL
FuentesSRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025

Origen de la bandera roja

DefiniciónBarrett's esophagus (intestinal metaplasia of the distal esophagus with goblet cells on biopsy after EGD performed for chronic GERD or Barrett's-specific surveillance) in an individual without a current esophageal adenocarcinoma diagnosis. Established precursor lesion to esophageal adenocarcinoma — annual progression rates: non-dysplastic Barrett's ~0.1-0.3%/year to EAC, low-grade dysplasia (LGD) ~0.7-2%/year, high-grade dysplasia (HGD) ~7-19%/year. Endoscopic surveillance and endoscopic eradication therapy (radiofrequency ablation, endoscopic mucosal resection) for dysplastic Barrett's substantially reduce EAC incidence and mortality. Prevention-persona RedFlag (§20 ratification 2026-05-18, v0.3 chronic-condition pilot).
Dirección clínicainvestigación
Categoríaotros

Lógica de activación

{
  "any_of": [
    {
      "finding": "barretts_esophagus_diagnosis_confirmed",
      "value": true
    },
    {
      "finding": "barretts_esophagus_with_dysplasia_low_grade",
      "value": true
    },
    {
      "finding": "barretts_esophagus_with_dysplasia_high_grade",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notas

v0.3 chronic-condition prevention pilot — Barrett's esophagus. Prevention-persona RedFlag (CHARTER §3 amended 2026-05-18 Path A, HCP-mediated). Fires when patient profile shows confirmed Barrett's esophagus (with or without dysplasia) AND no confirmed esophageal adenocarcinoma. Engine routes such patients to a PreventionPlan with 2 tracks: intensified EGD surveillance per ACG/NCCN cadences (IND-BARRETTS-ESOPHAGUS-PREVENTION-SURVEILLANCE) as the standard pathway; routine q5y EGD observation (IND-BARRETTS-ESOPHAGUS- PREVENTION-OBSERVATION) as the alternative — appropriate ONLY for confirmed non-dysplastic Barrett, not for any dysplasia grade. Evidence for surveillance + endoscopic eradication therapy reducing EAC incidence: HGD ablation reduces progression to EAC by ~75% vs observation (Shaheen et al. JAMA 2014; AIM-Dysplasia trial). LGD ablation reduces progression to HGD/EAC by ~75% (SURF trial, Phoa et al. JAMA 2014). For non-dysplastic Barrett, surveillance does not reduce incidence but improves earliest-stage detection. Dysplasia management: LGD → endoscopic eradication therapy (RFA ± EMR for visible lesions) OR intensified surveillance q6-12mo if patient declines. HGD → endosc...

Utilizado por

Indicación

Señal de alerta